As the RAS is known to be activated in heart failure patients [6, 7], various therapeutic approaches involving RAS inhibition, including the use of angiotensin converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs), have been developed in the past decades. The gene discussed is ACE; the disease is heart failure.